Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × temsirolimus × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4 Neoplasm Metastasis 3 Sarcoma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Breast Neoplasms 2 Urologic Neoplasms 1 Thyroid Neoplasms 1 Soft Tissue Neoplasms 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Recurrence 1 Pharyngeal Neoplasms 1 PRETEXT I Hepatoblastoma 1 Neurofibromatosis 2 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms, Mesothelial 1 Mouth Neoplasms 1 Melanoma 1 Lymphangioleiomyomatosis 1 Lung Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Erdheim-Chester Disease 1 Endometrial Adenocarcinoma 1 Endocrine Gland Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Desmoplastic Small Round Cell Tumor 1 Colonic Neoplasms 1

Interventions

Nivolumab 63 pembrolizumab 62 cabozantinib 43 Ipilimumab 33 Magnetic Resonance Spectroscopy 30 Specimen Handling 26 lenvatinib 21 Axitinib 20 belzutifan 16 Sunitinib 16 Radiosurgery 13 Biopsy 13 atezolizumab 10 Everolimus 10 CTLA-4 Antigen 10 pazopanib 9 avelumab 8 Radiotherapy 8 Bevacizumab 8 fludarabine 6 cemiplimab 6 aldesleukin 6 Standard of Care 6 Nephrectomy 6 Immunoglobulin G 6 Cyclophosphamide 6 toripalimab 5 spartalizumab 5 Paclitaxel 5 tivozanib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02184416 2026-02-27

ADONIS

Pfizer

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡